COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
-
Cross, Anne H. (Department of Neurology. Washington University)
;
Delgado, Silvia (University of Miami Miller School of Medicine) ;
Habek, Mario (University Hospital Center Zagreb. University of Zagreb. School of Medicine) ;
Davydovskaya, Maria (Moscow State Public Healthcare InsCity Clinical Hospital 24) ;
Ward, Brian J. (Infectious Diseases Division. Research Institute of the McGill University Health Centre) ;
Cree, Bruce A. C (UCSF Weill Institute for Neurosciences. Department of Neurology. University of California San Francisco) ;
Totolyan, Natalia (First Saint Petersburg State Medical University) ;
Pingili, Ratnakar (Novartis Pharmaceuticals Corporation) ;
Mancione, Linda (Novartis Pharmaceuticals Corporation) ;
Hu, Xixi (Novartis Pharmaceuticals Corporation) ;
Sullivan, Roseanne (Novartis Pharmaceuticals Corporation) ;
Su, Wendy (Novartis Pharmaceuticals Corporation) ;
Zielman, Ronald (Novartis Pharma B.V.) ;
Gupta, Ayan Das (Novartis Healthcare Private Limited) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron) ;
Winthrop, Kevin (School of Public Health at Oregon Health and Science University) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
guest ::
Subscribe to this discussion. You will then receive all new comments by email.
